Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to understand how bariatric surgery affects patients with metabolic syndrome over both the short and long term. We will track changes in blood pressure and other health indicators for up to 10 years after surgery. The goal is to see whether surgery can provide lasting benefits for controlling blood pressure and improving overall health in patients with metabolic syndrome.
Metabolic syndrome (MetS) is a combination of obesity, high blood pressure, abnormal blood sugar, and lipid disorders. It greatly increases the risk of heart disease, stroke, and type 2 diabetes. In Asian populations, MetS often appears at lower body mass index (BMI) levels than in Western countries, making it a growing public health concern even among individuals without severe obesity.
Bariatric surgery has been proven to help patients lose weight and improve blood sugar, blood pressure, and cholesterol levels. However, most studies have been done in patients with severe obesity. There is limited real-world evidence on how surgery affects patients with MetS at lower BMI levels, especially over the long term. In addition, the short-term biological changes that occur immediately after surgery are not fully understood.
This study is a multicenter prospective cohort including patients who had bariatric surgery in three hospitals in China. Patients are being followed for up to 10 years after surgery.
The primary outcome is improvement or resolution of MetS, defined by standardized criteria including BMI, blood pressure, fasting glucose, and lipid levels. Secondary outcomes include changes in individual risk factors, reduction in medication use, and the proportion of patients free of MetS over time.
By providing both short-term and long-term data, this study will clarify how bariatric surgery affects the full course of MetS. The results will help identify patients who may benefit most, guide treatment recommendations, and support better prevention of cardiovascular and metabolic diseases in Asian populations.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Weight | postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years | |
| Body Mass Index | postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years | |
| Systolic blood pressure | postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years | |
| Diastolic blood pressure | postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years | |
| Status of hypertension | postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years | |
| Fasting blood glucose | postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years | |
| Total cholesterol | postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years | |
| Triglycerides | postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years |
| Measure | Description | Time Frame |
|---|---|---|
| Glycated hemoglobin | postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years | |
| Low-density lipoprotein (LDL) | postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
The study population consists of adult patients aged 18 to 65 years who were scheduled to undergo bariatric surgery, including laparoscopic Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG), at three participating medical centers in China. Patients were selected based on guideline-based indications for bariatric surgery at the time of recruitment. For the primary analysis, only patients with hypertension were included, defined as meeting at least one of the following criteria: (1) systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg; (2) self-reported or physician-diagnosed hypertension; or (3) current use of antihypertensive medications. Patients with coexisting cardiac insufficiency, renal dysfunction, contraindications to surgery or anesthesia, or who declined participation were excluded. Additional exclusions during the data analysis phase included patients who experienced severe postoperative adverse events within 7 days, had fewer tha
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| China-Japan Friendship Hospital | Beijing | Beijing Municipality | 100029 | China | ||
| Jinshazhou Hospital of Guangzhou University of Chinese Medicine |
Not provided
| ID | Term |
|---|---|
| D024821 | Metabolic Syndrome |
| D006973 | Hypertension |
| D009765 | Obesity |
| ID | Term |
|---|---|
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
blood and urine
| High-density lipoprotein (HDL) | postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years |
| excess weight loss (EWL%) | postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years |
| Fasting insulin | postoperative day 1 to 7, 3 months, 6 months, 1 year, 5 years, and 10 years |
| Guangzhou |
| Guangdong |
| 510168 |
| China |
| The third xiangya hospital of Central South University | Changsha | Hunan | 410013 | China |
| D009750 |
| Nutritional and Metabolic Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |